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810Objectives: Randomized controlled trials of permanent atrial fibrillation ablation surgery have shown improved
outcomes compared with control patients undergoing concomitant cardiac surgery. Little has been reported
regarding patients with paroxysmal atrial fibrillation. We hypothesized that treating paroxysmal atrial fibrillation
during cardiac surgerywould not adversely affect the perioperative risk andwould improve themidtermoutcomes.
Methods: From April 2004 to June 30 2012, 4947 patients (excluding those with transcatheter aortic valve im-
plants, left ventricular assist devices, trauma, transplantation, and isolated atrial fibrillation surgery) underwent
cardiac surgery, and 1150 (23%) had preoperative atrial fibrillation. Of these, 552 (48%) had paroxysmal atrial
fibrillation. Three groups were compared using propensity score matching: treated (n ¼ 423, 77%), untreated
(n ¼ 129, 23%), and no atrial fibrillation (n ¼ 3797).
Results: The treated patients had 30-day mortality similar to that of the untreated patients and those without
atrial fibrillation. They had fewer perioperative complications (26% vs 46%, P ¼ .001), greater freedom
from atrial fibrillation at the last follow-up visit (81% vs 60%, P ¼ .007), and lower mortality (hazard ratio
0.47, P¼ .007) compared with the untreated patients. Compared with those without atrial fibrillation, the treated
patients had fewer perioperative complications (25% vs 48%, P<.001), lower freedom from atrial fibrillation at
the last follow-up visit (84% vs 93%, P ¼ .001), and similar mortality.
Conclusions: Concomitant surgical ablation of paroxysmal atrial fibrillation was not associated with increased
perioperative risk. The treated patients had greater late freedom from atrial fibrillation and midterm survival
compared with the untreated patients, and similar midterm survival compared with the patients without atrial
fibrillation. These results suggest that paroxysmal atrial fibrillation warrants treatment consideration in select
patients undergoing cardiac surgery. (J Thorac Cardiovasc Surg 2013;146:810-23)Earn CME credits at
http://cme.ctsnetjournals.org
Preoperative atrial fibrillation (AF) in patients undergoing
cardiac surgery procedures is an independent risk factor
for late adverse events, including cardiac complications
and reduced survival.1-6 The use of surgical ablation for
preoperative AF during cardiac surgery increased rapidly
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The Journal of Thoracic and Cardiovascular Surgsets; however, surgeons still hesitate to perform this
procedure.7 Of the patients in the Society of Thoracic Sur-
geons (STS) database, only 38% of those undergoing car-
diac surgery with preoperative AF were treated at surgery,
although AF ablation added only 9 minutes of crossclamp
and cardiopulmonary bypass time without increasing mor-
bidity and mortality.8 For these successfully treated pa-
tients, it has been suggested that their survival can be
restored to that of patients without preoperative AF.9
Multiple prospective randomized clinical trials have been
performed of patients with ‘‘permanent’’ AF undergoing
mitral valve or coronary artery bypass grafting (CABG),
with all documenting freedom from AF (FFAF) greater
than that of the untreated control patients, as summarized
in a joint Heart Rhythm Society (HRS)/STS document.10-16
Just as in the large database report and single-center studies,
no indication was found that adding AF ablation to cardiac
surgery increased the patients’ perioperative morbidity or
mortality, except for an increased risk of permanent pace-
maker placement (hazard ratio [HR], 1.26).8,9,17,18 The
position statement published by the HRS, STS, and others
has stated ‘‘it is appropriate to consider all patients with
symptomatic AF undergoing other cardiac surgery for AF
ablation.’’10 However, little has been reported specifically
about the treatment of patients with paroxysmal AF (PAF)ery c October 2013
Abbreviations and Acronyms
AAD ¼ antiarrhythmic drug
AF ¼ atrial fibrillation
BA ¼ biatrial
CABG ¼ coronary artery bypass grafting
FFAF ¼ freedom from atrial fibrillation
HR ¼ hazard ratio
HRS ¼ Heart Rhythm Society
LA ¼ left atrial
NoAF ¼ patients without preoperative PAF who
received no AF treatment
PAF ¼ paroxysmal AF
PS ¼ propensity score
PVI ¼ pulmonary vein isolation
STS ¼ Society of Thoracic Surgeons
TrPAF ¼ patients with PAF who received AF
treatment during cardiac surgery
UntrPAF ¼ patients with PAF who did not receive
AF treatment
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PAFmight resolvewithout ablation after otherwise success-
ful cardiac surgery.19 Although the cardiac pathologic entity
can be addressed by valve operations or CABG, the patient
might continue to have AF after surgery because of under-
lying conditions (eg, advanced age or dilated atria) and,
therefore, might be at risk of the adverse outcomes of AF,
such as thromboembolism and increased stroke risk and
complications from anticoagulation or medication to main-
tain sinus rhythm or rate control. In addition, the patient
could have continued symptoms from PAF.
In the present report,we investigatedwhether treatingPAF
during cardiac surgery might improve FFAF compared with
untreated PAF, without increasing the perioperative risk, and
whether this has an affect onmidterm survival.We compared
these outcomes in 3 groups: patients with PAF who received
AF treatment during cardiac surgery (TrPAF); patients with
PAF who did not receive AF treatment (UntrPAF); and
patients without preoperative PAF (NoAF) who received
no AF treatment. If TrPAF patients have better outcomes,
concomitant ablation could be recommended for select
patients. We also compared the midterm survival in the
‘‘success’’ patients, who had achieved FFAF, and compared
that with that of the ‘‘failures,’’ who were in AF. Further-
more, we studied the outcomes of the patients with biatrial
(BA) lesions compared with only left atrial (LA) lesions.
METHODS
Patients and AF Monitoring Protocol
From April 2004 to July 2012, 4947 patients (excluding those with
transcatheter aortic valve implants, ventricular assist devices, trauma,
transplant, and isolated AF ablation procedures) underwent cardiac sur-
gery, and 1150 (23%) had preoperative AF. Of the 1150 patients withThe Journal of Thoracic and CaAF, 552 (49%) had PAF and 423 (77%) were treated concomitant to other
cardiac operations (TrPAF).
The data of all patients were in the Bluhm Cardiovascular Institute’s
Clinical Trial Units Cardiovascular Research Database. The preoperative,
operative, and postoperative variables were retrieved from the database
and by medical record review, and the data were de-identified before anal-
ysis. Any subject refusing participation in the project was not included in
the present analysis. The institutional review board at Northwestern Uni-
versity approved the database (project no. STU00012288).
These patients had been prospectively followed up since January 2006,
when a dedicated AF clinical/research nurse was hired. The postoperative
AF management protocol was standardized in collaboration with the elec-
trophysiologists. The patients were discharged with antiarrhythmic drugs
(AADs) and anticoagulant medication (warfarin), if not contraindicated.
For any patients with postoperative persistent atrial flutter or AF, cardiover-
sion was recommended 6 to 8 weeks after surgery. Mobile cardiac outpa-
tient telemetry (CardioNet, Conshohocken, Pa, or ACT Ambulatory
Cardiac Telemetry, LifeWatch Corp, Rosemont, Ill) was recommended at
3 months. If this was not available, attempts were made to have the patient
wear an AF Express (LifeWatch Corp) monitor for 30 days or a Holter
monitor at the cardiologist’s discretion. Patients with dual-chamber im-
planted defibrillators or pacemakers had the mode-switch parameters acti-
vated to track atrial arrhythmias. The monitor results were also obtained
from the cardiac rehabilitation sessions. The AADs were withdrawn at
the discretion of the cardiologist and AF nurse if sinus rhythm had been
documented at 3 months and the patient had no symptoms suggesting
AF. Patients with persistent atrial flutter, AF, or atrial tachycardia were of-
fered referral to electrophysiology for catheter ablation. Monitoring with
mobile cardiac outpatient telemetry or 30-day event monitors was per-
formed again at 6 months, and anticoagulation was discontinued for the pa-
tients maintaining sinus rhythm without AADs at the discretion of the
cardiologist and, more recently, guided by the CHADS2 score, or the
CHA2DS2-VASc score more recently.
10 Summaries of these risk stratifica-
tion tools were provided to the referring cardiologists. The TrPAF group
and the referring cardiologists were given copies of these guidelines, and
telephone follow-up was performed by the AF nurses with the patients
within the first month and again at 3, 6, and 12 months to track their prog-
ress. All patients, regardless of AF history or treatment group, participating
in the Cardiovascular Research Database were sent surveys at 3, 6, and 12
months and annually. Copies of the medical records were obtained for any
procedures or hospitalizations to verify the self-reported events. This in-
tense postoperative monitoring protocol allowed us to report late AF out-
comes in accordance with the recommendations from the HRS and STS
documents.10 Although rhythm monitoring using a Holter monitor or
more extensive devices was advised, this was not a prospective trial with
study visits, and follow-up was largely performed by the referring cardiol-
ogists. In the TrAF cohort, 57% of the available follow-up data at 6 months
was from extensive monitoring. At later follow-up of 1 year or more, 54%
of the monitoring data came from these sources. The STS database defini-
tions were used for all variables. The STS risk score was not used to calcu-
late perioperative mortality, because it fails to account for patients with
preoperative AF. Instead, the Ambler mortality risk scores and the Euro-
pean system for cardiac operative risk evaluation were calculated.20,21
Survival was determined using the Social Security Death Index. The
mean follow-up period for the TrPAF, UntrPAF, and NoAF groups was
2.7  2.0, 2.6  2.0, and 2.8  2.1 years, respectively.Surgical Procedures
The patients with PAF underwent mitral valve surgery (n ¼ 296, 54%),
CABG (n¼ 198, 36%), aortic valve surgery (n¼ 228, 41%), and tricuspid
valve surgery (n¼ 102, 18%). Lesion sets were performed using bipolar ra-
diofrequency (Atricure Inc, West Chester, Ohio, or Medtronic, Minneapolis,
Minn) or cryothermy (Cooper Surgical, Shelton, Conn, or Atricure). The
TrPAF group underwent 1 of 4 AF lesion sets, with most consisting of therdiovascular Surgery c Volume 146, Number 4 811
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DLA-only maze procedure (n¼ 199, 47%). Others included pulmonary vein
isolation (PVI) (n¼ 119, 28%), the BAmaze (n¼ 85, 20%), and the classic
‘‘cut and sew’’ Coxmaze (n¼ 20, 5%). The decision to ablate and the choice
of the lesion setwas at the discretion of the surgeon in the operating room and
was performedwhen the benefit to risk ratio for ablation surgery was deemed
sufficiently high in accordance with the HRS/STS documents.10
Surgical procedures that require opening the left atrium can be easily
treated with AF ablation; therefore, of the 296mitral valve surgery patients,
ablation was added for 263 (88.9%). However, the aortic valve replace-
ment and CABG patients (n ¼ 229) were more likely to be left untreated
(n ¼ 80, 34.9%) or to undergo bilateral PVI (n ¼ 116, 50.7%). A few pa-
tients in the aortic valve replacement and/or CABG group (generally youn-
ger patients with symptomatic AF or a history of stroke) underwent a more
complete lesion set consisting of LA, BA, or the classic cut and sew maze
(n ¼ 33, 14.4%). The patients undergoing reoperation overall were less
likely to undergo AF ablation (52.7% vs 84.1% for those with a primary
operation; P< .001). Finally, variability existed among the surgeons in
the percentage of patients with PAF who were treated (35-85%, P<.001).
Statistical Analysis
Primary analyses were performed to compare, in pairwise fashion, the
outcomes in 3 patient groups: (1) TrPAF, (2) UntrPAF, and (3) NoAF. In
the secondary analyses, we compared the outcomes of those patients whose
AFwas surgically treated using LA lesions only with thosewith BA lesions.
To mitigate potential bias due to baseline imbalances, propensity score
(PS) matching methods were used. In both primary analyses, any 2 groups
compared were PS matched in a 3:1 fashion (larger vs smaller group) using
a greedymatching algorithm.A1:1PSmatching ratiowas used in the second-
ary analyses that compared theLAonly andBAgroups.Throughout, a caliper
size of 0.02 logit PS standard deviation unitswas used in the PSmatching pro-
cess. In every PSmodel, the explanatory variables included age, body surface
area, sex, ejection fraction, repeat sternotomy, coronary artery disease, pe-
ripheral vascular disease, cardiovascular disease, diabetes, elective case sta-
tus, dyslipidemia, hypertension, chronic obstructive pulmonary disease,
cerebrovascular accident history, New York Heart Association class III-IV,
previous myocardial infarction, previous congestive heart failure, and medi-
cation (lipid-lowering, AADs). The quality of covariate balance after PS
matching was assessed by comparing the kernel-smoothed PS histograms.
Continuous variables were summarized using the mean  standard de-
viation or median and interquartile range. Comparisons of continuous vari-
ables were done using t tests or the Wilcoxon rank sum test. For binary
variables, the proportions were calculated and compared using the chi-
square test or Fisher’s exact test.
The demographics, perioperative characteristics, and outcomes in the 3
original groups are summarized in Table 1. Data for the 3 PS-matched pri-
mary analyses are listed in Tables 2 (TrPAF vs UntrPAF), 3 (TrPAF vs
NoAF), and 4 (UntrPAFvsNoAF). The results of the secondary analysis com-
paring the PS-matched LA only and BA patients are listed in Table 5. Long-
term survivorship was summarized using Kaplan-Meier curves. Unadjusted
group comparisons were based on the log-rank test. Age and PS-adjusted
comparisons in the PS-matched groups used Cox regression models with ro-
bust covariance matrix. The feasibility of the proportional hazards assump-
tion was assessed visually. Summaries of survivorship and FFAF at last
follow-up without AAD are presented in Figures 1 and 2, respectively. Survi-
vorship byAF status at the last follow-up visit (success or failure) is shown by
the years since surgery and years since the last follow-up visit in Figure 3.
Throughout, a 2-sided 5% statistical significance level was used, without
multiplicity adjustments. All analyseswere performed using Statistical Anal-
ysis Systems, version 9.3 (SAS Institute Inc, Cary, NC).RESULTS
In the initial groups (Table 1), the TrPAF group was differ-
ent from the other 2 groups in several categories, including812 The Journal of Thoracic and Cardiovascular Surgage, ejection fraction, left atrial size, preoperative pacemaker
use, coronary artery disease, previous myocardial infarction,
congestive heart failure, and elective surgery status. The
TrPAF groupwasmore likely to undergomitral valve surgery
and tricuspid valve surgery. The TrPAF group also had fewer
perioperative complications (28%), a 2% rate of 30-daymor-
tality, and 85%were FFAFwithout AADs at follow-up, with
9% having undergone ablation at some point postoperatively.
The UntrPAF group was older and had a number of adverse
preoperative risk factors, including congestive heart failure,
advanced New York Heart Association class, previous myo-
cardial infarction, coronary artery disease, diabetes, dyslipi-
demia, cerebrovascular disease, lower ejection fraction,
higher creatinine, and more repeat sternotomies than the ab-
lated group. The UntrPAF group had more perioperative
complications (43%), a 6% rate of 30-day mortality, 66%
were FFAF without AADs at the last follow-up visit, and
5% underwent late ablation.
After PS matching, the TrPAF group (Table 2) had spent
less time in the intensive care unit (P ¼ .049) than had the
UntrPAF group, had fewer total complications (26% vs
46%,P¼ .001), had similar operative and 30-daymortality,
and had a significantly lower risk of all-cause overall mor-
tality (adjusted HR, 0.47; P ¼ .007; Figure 1). In addition,
the TrPAF group had higher FFAF at the last follow-up visit
(81% vs 60%, P ¼ .007) and presented with a strong trend
for greater FFAF without AADs at the last follow-up visit
(82% vs 66%, P ¼ .054) compared with the patients with
PAF who were untreated. No significant differences were
found in freedom from ablation (90% vs 96%, P ¼ .36)
or stroke (95% vs 98%, P ¼ .68).
When PS matching the TrPAF and NoAF patients (Table
3), the TrPAF group had longer perfusion times (16minutes,
P<.001) and crossclamp times (6 minutes, P¼ .006), a lon-
ger hospital stay (median, 7 vs 6 days), fewer complications
overall (25% vs 48%, P<.001). The operative, 30-day, and
all-cause mortality was not significantly different. Patients
without a history of AF had higher rates of FFAF through-
out, both with and without AADs. The stroke rate was sim-
ilar in the 2 groups (P ¼ .24).
Compared with the NoAF group, the PS-matched Un-
trPAF patients (Table 4) had similar perfusion and cross-
clamp times but spent a longer time in the intensive care
unit (52 vs 45 hours, P ¼ .037) and had a longer hospital
stay (median, 8 vs 7 days, P ¼ .004). They also required
more prolonged ventilation (29% vs 13%, P<.001). The
operative and 30-day mortality were similar; however, the
UntrPAF patients had an increased unadjusted all-cause
mortality (HR, 1.64; P ¼ .024), accompanied by a trend
in the adjusted analyses (HR, 1.47; P¼ .099). Patients with-
out a history of AF had higher rates of FFAF throughout, ex-
cept for FFAF without AADs at 1 year. The freedom from
stroke and ablation rates were similar in the 2 groups
(P ¼ .73 and P ¼ .38, respectively).ery c October 2013
TABLE 1. Preoperative and perioperative characteristics and outcomes in original groups
Variable UntrPAF (n ¼ 129) TrPAF (n ¼ 423) NoAF (n ¼ 3797) P value
Age (y) 68.7  13.7 66.5  11.8 61.7  14.1 <.001
Ejection fraction (%) <.001
Median 55.0 57.0 60.0
Q1, Q3 40.0, 60.0 50.0, 61.5 50.0, 64.0
Female sex 42 (33) 176 (42) 1295 (34) .008
Left atrial size (cm) <.001
Median 4.2 4.3 3.8
Q1, Q3 3.7, 4.7 3.9, 4.9 3.3, 4.3
AF duration (y) .43
Median 1.0 1.0 —
Q1, Q3 0.5, 4.5 0.5, 5.0 —
Hypertension 91 (71) 285 (67) 2526 (67) .61
Cerebrovascular disease 26 (20) 52 (12) 441 (12) .013
Previous stroke 12 (10) 31 (8) 248 (7) .30
Previous pacemaker 21 (16) 46 (11) 103 (3) <.001
Previous MI 37 (29) 56 (13) 712 (19) <.001
Congestive heart failure 59 (46) 165 (39) 915 (24) <.001
NYHA class III-IV 64 (50) 153 (36) 1130 (30) <.001
Coronary artery disease 82 (66) 173 (41) 2117 (58) <.001
Repeat sternotomy 62 (48) 69 (16) 454 (12) <.001
Elective surgery 89 (69) 364 (86) 2945 (78) <.001
CABG 54 (42) 144 (34) 1913 (50) <.001
Aortic valve surgery 70 (54) 158 (37) 1517 (40) .002
Mitral valve surgery 33 (26) 263 (62) 949 (25) <.001
Tricuspid valve surgery 14 (11) 88 (21) 185 (5) <.001
Perfusion time (min) <.001
Median 116.5 120.0 106.0
Q1, Q3 86.0, 160.0 94.0, 149.5 79.0, 142.0
Crossclamp time (min) .12
Median 91.0 89.0 87.0
Q1, Q3 73.0, 118.0 70.0, 115.0 66.0, 115.0
Total ICU duration (h) <.001
Median 54.1 45.8 31.0
Q1, Q3 27.2, 134.2 25.7, 81.0 24.0, 65.0
Length of stay (d) <.001
Median 8.0 7.0 6.0
Q1, Q3 6.0, 11.0 5.0, 9.0 5.0, 8.0
Readmitted to ICU 12 (9) 33 (8) 191 (5) .008
Complications 56 (43) 117 (28) 1506 (40) <.001
Reoperation for bleeding 8 (6) 10 (2) 169 (4) .07
Predischarge pacemaker 6 (5) 27 (6) 92 (2) <.001
Prolonged ventilation>24 h 36 (28) 50 (12) 361 (10) <.001
Ambler score (%) 12.0  9.7 8.1  7.7 4.8  6.5 <.001
Logistic EuroSCORE (%) 26.5  21.8 12.7  13.2 11.2  13.2 <.001
Operative mortality 10 (8) 10 (2) 94 (2) .001
30-Day mortality 8 (6) 10 (2) 78 (2) .007
Readmission within 30 d 15 (13) 57 (14) 437 (12) .49
FFAF at 1 y (d 274-455) 24/33 (73) 154/198 (78) 578/605 (96) <.001
FFAF at last follow-up 48/66 (73) 309/363 (85) 1544/1611 (96) <.001
FFAF at 1 y, no AADs 14/17 (82) 98/128 (77) 347/360 (96) <.001
FFAF at last follow-up, no AADs 37/49 (76) 256/301 (85) 1211/1260 (96) <.001
FF ablation 69/73 (95) 320/352 (91) 1899/1927 (99) <.001
FF stroke 75/77 (97) 343/361 (95) 1969/2024 (97) .067
Data are presented as mean  standard deviation, n (%), or median (quartiles). UntrPAF, Patients with paroxysmal atrial fibrillation who did not receive atrial fibrillation treat-
ment; TrPAF, patients with paroxysmal atrial fibrillation who received atrial fibrillation treatment during cardiac surgery; NoAF, patients without preoperative paroxysmal atrial
fibrillation who received no atrial fibrillation treatment;Q, quartile; AF, atrial fibrillation;MI,myocardial infarction; NYHA,NewYork Heart Association;CABG, coronary artery
bypass grafting; ICU, intensive care unit; EuroSCORE, European system for cardiac operative risk evaluation; FFAF, freedom from atrial fibrillation; AADs, antiarrhythmic drugs;
FF, freedom from.
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TABLE 2. Preoperative and perioperative characteristics and outcomes in PS-matched treated and untreated PAF patient groups
Variable UntrPAF (n ¼ 80) TrPAF (n ¼ 166) P value
Age (y) 67.7  14.8 67.9  11.6 .93
Ejection fraction (%) .87
Median 55.0 55.0
Q1, Q3 43.0, 60.0 45.0, 60.0
Female sex 28 (35) 62 (37) .72
Left atrial size (cm) .11
Median 4.1 4.3
Q1, Q3 3.6, 4.7 3.8, 4.8
AF duration (y) .48
Median 1.0 1.0
Q1, Q3 0.5, 5.0 0.5, 5.0
Hypertension 56 (70) 118 (71) .86
Cerebrovascular disease 15 (19) 30 (18) .90
Previous stroke 8 (11) 19 (12) .78
Previous pacemaker 9 (11) 22 (13) .66
Previous MI 20 (25) 32 (19) .30
Congestive heart failure 35 (44) 63 (38) .38
NYHA class III-IV 35 (44) 71 (43) .88
Coronary artery disease 47 (60) 98 (60) .98
Repeat sternotomy 23 (29) 42 (25) .57
Elective surgery 59 (74) 131 (79) .37
CABG 37 (46) 73 (44) .74
Aortic valve surgery 40 (50) 74 (45) .42
Mitral valve surgery 29 (36) 68 (41) .48
Tricuspid valve surgery 11 (14) 25 (15) .79
Perfusion time (min) .34
Median 125.0 121.0
Q1, Q3 88.0, 164.0 93.0, 149.0
Crossclamp time (min) .05
Median 100.0 89.0
Q1, Q3 75.0, 127.0 69.0, 113.0
Total ICU duration (h) .049
Median 52.3 46.5
Q1, Q3 26.1, 143.5 25.0, 96.0
Length of stay (d) .18
Median 8.0 7.0
Q1, Q3 6.0, 12.0 6.0, 10.0
Readmitted to ICU 8 (10) 15 (9) .81
Complications 37 (46) 43 (26) .001
Reoperation for bleeding 5 (6) 5 (3) .23
Predischarge pacemaker 3 (4) 6 (4) .96
Prolonged ventilation>24 h 25 (31) 22 (13) <.001
Ambler score (%) 11.4  10.9 8.9  8.3 .045
Logistic EuroSCORE (%) 22.9  20.2 16.1  16.1 .005
Operative mortality 5 (6) 4 (2) .13
30-Day mortality 4 (5) 4 (2) .28
Readmission within 30 d 9 (12) 23 (14) .62
FFAF at 1 y (d 274-455) 16/22 (73) 63/83 (76) .76
FFAF at last follow-up 24/40 (60) 110/136 (81) .007
FFAF at 1 y, no AADs 9/11 (82) 43/57 (75) 1.00
FFAF at last follow-up, no AADs 21/32 (66) 93/114 (82) .054
FF ablation 44/46 (96) 125/139 (90) .36
FF stroke 47/48 (98) 138/145 (95) .68
Data are presented as mean  standard deviation, n (%), or median (quartiles). PS, Propensity score; UntrPAF, patients with PAF who did not receive AF treatment; TrPAF,
patients with PAF who received AF treatment during cardiac surgery; Q, quartile; AF, atrial fibrillation; MI, myocardial infarction; NYHA, New York Heart Association;
CABG, coronary artery bypass grafting; ICU, intensive care unit; EuroSCORE, European system for cardiac operative risk evaluation; FFAF, freedom from atrial fibrillation;
AADs, antiarrhythmic drugs; FF, freedom from.
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TABLE 3. Preoperative and perioperative characteristics and outcomes in PS-matched TrPAF and NoAF groups
Variable TrPAF (n ¼ 343) NoAF (n ¼ 879) P value
Age (y) 66.3  11.9 65.5  12.9 .35
Ejection fraction (%) .06
Median 58.0 60.0
Q1, Q3 50.0, 62.0 50.0, 65.0
Female sex 132 (38) 324 (37) .60
Left atrial size (cm) <.001
Median 4.3 4.0
Q1, Q3 3.8, 4.8 3.6, 4.5
AF duration (y)
Median 1.0 — —
Q1, Q3 0.5, 4.0 — —
Hypertension 230 (67) 605 (69) .55
Cerebrovascular disease 43 (13) 120 (14) .61
Previous stroke 27 (8) 66 (8) .89
Previous pacemaker 33 (10) 36 (4) <.001
Previous MI 42 (12) 125 (14) .37
Congestive heart failure 133 (39) 309 (35) .24
NYHA class III-IV 117 (34) 283 (32) .52
Coronary artery disease 146 (43) 387 (45) .58
Repeat sternotomy 51 (15) 113 (13) .35
Elective surgery 295 (86) 761 (87) .79
CABG 125 (36) 341 (39) .45
Aortic valve surgery 131 (38) 341 (39) .85
Mitral valve surgery 203 (59) 486 (55) .22
Tricuspid valve surgery 61 (18) 118 (13) .05
Perfusion time (min) <.001
Median 120.0 104.0
Q1, Q3 94.0, 148.0 78.0, 142.0
Crossclamp time (min) .006
Median 89.0 83.0
Q1, Q3 71.0, 116.0 64.0, 113.0
Total ICU duration (h) .17
Median 45.2 42.1
Q1, Q3 25.1, 79.6 24.5, 73.1
Length of stay (d) .002
Median 7.0 6.0
Q1, Q3 5.0, 9.0 5.0, 9.0
Readmitted to ICU 26 (8) 55 (6) .40
Complications 87 (25) 420 (48) <.001
Reoperation for bleeding 8 (2) 52 (6) .009
Predischarge pacemaker 16 (5) 43 (5) .87
Prolonged ventilation>24 h 40 (12) 97 (11) .76
Ambler score (%) 7.7  7.4 6.2  7.2 .001
Logistic EuroSCORE (%) 12.2  12.2 13.0  13.9 .32
Operative mortality 10 (3) 31 (4) .59
30-Day mortality 10 (3) 26 (3) .97
Readmission within 30 d 46 (14) 108 (13) .61
FFAF at 1 y (d 274-455) 122/160 (76) 149/159 (94) <.001
FFAF at last follow-up 247/293 (84) 394/423 (93) <.001
FFAF at 1 y, no AADs 82/107 (77) 95/101 (94) <.001
FFAF at last follow-up, no AADs 205/243 (84) 327/353 (93) .001
FF ablation 254/283 (90) 514/528 (97) <.001
FF stroke 277/292 (95) 532/551 (97) .24
Data are presented as mean  standard deviation, n (%), or median (quartiles). TrPAF, Patients with PAF who received AF treatment during cardiac surgery; NoAF, patients
without preoperative PAF who received no AF treatment; Q, quartile; AF, atrial fibrillation; MI, myocardial infarction; NYHA, New York Heart Association; CABG, coronary
artery bypass grafting; ICU, intensive care unit; EuroSCORE, European system for cardiac operative risk evaluation; FFAF, freedom from atrial fibrillation; AADs, antiarrhythmic
drugs; FF, freedom from.
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TABLE 4. Preoperative and perioperative characteristics and outcomes in PS-matched UntrPAF and NoAF groups
Variable UntrPAF (n ¼ 114) NoAF (n ¼ 314) P value
Age (y) 68.1  13.9 67.8  12.5 .85
Ejection fraction (%) .51
Median 55.0 55.0
Q1, Q3 40.0, 60.0 42.0, 60.0
Female sex 39 (34) 109 (35) .92
Left atrial size (cm) .24
Median 4.2 4.0
Q1, Q3 3.6, 4.7 3.5, 4.6
AF duration (y) —
Median 1.0 —
Q1, Q3 0.5, 5.0 —
Hypertension 79 (69) 223 (71) .73
Cerebrovascular disease 21 (18) 74 (24) .26
Previous stroke 11 (11) 38 (14) .41
Previous pacemaker 15 (13) 21 (7) .033
Previous MI 30 (26) 95 (30) .43
Congestive heart failure 48 (42) 127 (40) .76
NYHA class III-IV 51 (45) 142 (45) .93
Coronary artery disease 72 (66) 208 (69) .62
Repeat sternotomy 49 (43) 144 (46) .60
Elective surgery 81 (71) 229 (73) .70
CABG 50 (44) 157 (50) .26
Aortic valve surgery 60 (53) 168 (54) .87
Mitral valve surgery 31 (27) 88 (28) .87
Tricuspid valve surgery 11 (10) 20 (6) .25
Perfusion time (min) .67
Median 118.0 118.0
Q1, Q3 86.0, 160.5 89.0, 170.0
Crossclamp time (min) .81
Median 94.0 90.0
Q1, Q3 70.0, 123.0 72.0, 126.0
Total ICU duration (h) .037
Median 52.2 45.0
Q1, Q3 26.2, 130.7 26.0, 93.0
Length of stay (d) .004
Median 8.0 7.0
Q1, Q3 6.0, 12.0 5.0, 10.0
Readmitted to ICU 11 (10) 17 (5) .12
Complications 49 (43) 145 (46) .56
Reoperation for bleeding 7 (6) 14 (4) .48
Predischarge pacemaker 5 (4) 14 (4) .97
Prolonged ventilation>24 h 33 (29) 42 (13) <.001
Ambler score (%) 11.6  10.0 8.9  8.3 .005
Logistic EuroSCORE (%) 25.4  22.0 21.9  17.9 .10
Operative mortality 7 (6) 14 (4) .48
30-Day mortality 6 (5) 12 (4) .51
Readmission within 30 d 12 (11) 44 (15) .37
FFAF at 1 y (d 274-455) 23/32 (72) 44/48 (92) .019
FFAF at last follow-up 42/60 (70) 115/123 (94) <.001
FFAF at 1 y, no AADs 13/16 (81) 24/26 (92) .35
FFAF at last follow-up, no AADs 34/46 (74) 89/97 (92) .004
FF ablation 64/67 (96) 144/147 (98) .38
FF stroke 69/71 (97) 151/159 (95) .73
Data are presented as mean standard deviation, n (%), or median (quartiles).UntrPAF, Patients with PAFwho did not receive AF treatment;NoAF, patients without preoperative
PAF who received no AF treatment; Q, quartile; AF, atrial fibrillation; MI, myocardial infarction; NYHA, New York Heart Association; CABG, coronary artery bypass grafting;
ICU, intensive care unit; EuroSCORE, European system for cardiac operative risk evaluation; FFAF, freedom from atrial fibrillation; AADs, antiarrhythmic drugs; FF, freedom
from.
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TABLE 5. Preoperative and perioperative characteristics and outcomes in PS-matched patients with LA only and BA AF ablation lesions
Variable LA only (n ¼ 49) BA (n ¼ 49) P value
Age (y) 64.6  11.7 65.3  10.4 .74
Ejection fraction (%) .64
Median 55.0 56.0
Q1, Q3 50.0, 60.0 46.0, 60.0
Female sex 24 (49) 22 (45) .69
Left atrial size (cm) .51
Median 4.4 4.6
Q1, Q3 4.1, 5.0 4.2, 5.2
AF duration (y) .036
Median 0.8 1.5
Q1, Q3 0.5, 3.0 0.8, 6.5
Hypertension 27 (55) 28 (57) .84
Cerebrovascular disease 7 (14) 5 (10) .54
Previous stroke 6 (13) 3 (6) .31
Previous pacemaker 3 (6) 4 (8) .69
Previous MI 5 (10) 3 (6) .46
Congestive heart failure 23 (47) 15 (31) .10
NYHA class III-IV 17 (35) 13 (27) .38
Coronary artery disease 14 (30) 15 (31) .88
Repeat sternotomy 13 (27) 10 (20) .47
Elective surgery 42 (86) 44 (90) .54
CABG 13 (27) 14 (29) .82
Aortic valve surgery 8 (16) 12 (24) .32
Mitral valve surgery 46 (94) 43 (88) .29
Tricuspid valve surgery 17 (35) 14 (29) .51
Perfusion time (min) .83
Median 120.0 121.0
Q1, Q3 100.0, 141.0 103.0, 143.0
Crossclamp time (min) .70
Median 90.0 89.0
Q1, Q3 72.0, 114.0 79.0, 112.0
Total ICU duration (h) .89
Median 46.4 42.1
Q1, Q3 25.0, 73.3 25.0, 90.6
Length of stay (d) .51
Median 8.0 7.0
Q1, Q3 6.0, 10.0 5.0, 9.0
Readmitted to ICU 4 (8) 5 (10) .73
Complications 12 (24) 18 (37) .19
Reoperation for bleeding 0 (0) 0 (0) —
Predischarge pacemaker 4 (8) 7 (14) .34
Prolonged ventilation>24 h 7 (14) 7 (14) 1.00
Ambler score (%) 10.4  8.8 7.8  6.6 .10
Logistic EuroSCORE (%) 11.8  12.9 9.7  9.4 .36
30-Day operative mortality 2 (4) 0 (0) .15
Readmission within 30 d 7 (15) 12 (24) .24
FFAF at 1 Year (day 274-455) 17/22 (77) 21/28 (75) .85
FFAF at last follow-up 32/41 (78) 40/44 (91) .10
FFAF at 1 y, no AADs 9/12 (75) 14/19 (74) 1.00
FFAF at last follow-up, no AADs 26/33 (79) 35/39 (90) .32
FF ablation 35/37 (95) 36/43 (84) .17
FF stroke 35/38 (92) 43/44 (98) .33
Data are presented as mean  standard deviation, n (%), or median (quartiles). LA, Left atrial; BA, biatrial; Q, quartile; AF, atrial fibrillation;MI, myocardial infarction; NYHA,
New York Heart Association; CABG, coronary artery bypass grafting; ICU, intensive care unit; EuroSCORE, European system for cardiac operative risk evaluation; FFAF, free-
dom from atrial fibrillation; AADs, antiarrhythmic drugs; FF, freedom from.
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FIGURE 1. Summary of survivorship in the (A) original and (B-D) propensity score (PS)–matched groups. PAF, Paroxysmal atrial fibrillation; AF, atrial
fibrillation; HR, hazard ratio; CI, confidence interval.
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termine whether AF itself affected survival (not just abla-
tion treatment of AF; Figure 3). For patients in the TrPAF
and NoAF groups, survival was lower for those in AF at
the last follow-up visit. For the UntrPAF group, no differ-
ence was found in overall survival between those in AF
and those with FFAF.
A secondary PS-matched analysis (Table 5) revealed no
significant differences between the LA only and BA lesions818 The Journal of Thoracic and Cardiovascular Surgin intraoperative characteristics and short- or midterm out-
comes, including mortality, complications, and FFAF (90%
BAvs 79% LA, P¼ .32). A strong trend for lower all-cause
mortality was observed in the BA group (adjusted HR, 0.35;
P ¼ .052; unadjusted HR, 0.35; P ¼ .048).
In the TrPAF group, no significant differences were found
in FFAF without AADs at the last follow-up visit by lesion
set: classic maze, 85% (11 of 13); LA 82% (115 of 140),
BA, 87% (53 of 61); and PVI, 89% (77 of 87); P ¼ .59.ery c October 2013
FIGURE 2. Summary of freedom from atrial fibrillation (AF)without antiarrhythmic drugs (AADs) at the last follow-up visit in the (A) original and (B-D)
propensity score (PS)–matched groups. PAF, Paroxysmal atrial fibrillation.
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The primary finding of the present study was that no in-
dications were found that adding AF ablation surgery in-
creased the risks of the procedure. Compared with the
matched patients with untreated PAF, the TrPAF patients
had no increase in new permanent pacemaker implantation
(4% in each group) and no increase in bleeding. They also
had a lower risk of overall complications (26% vs 46%,
P ¼ .001) and prolonged ventilation. The perioperative re-
sults in the matched TrPAF patients compared with thoseThe Journal of Thoracic and Cawith NoAF showed slightly longer crossclamp (6 minutes)
and perfusion (16 minutes) times, likely because of the time
required for ablation. Complications overall were lower for
the TrPAF group (25% vs 48%, P< .001), bleeding was
lower (2% vs 6%, P ¼ .009), and new pacemaker use
was the same (5%). Therefore, when considering the risk
to benefit ratio of adding PAF surgery, no concerns were
raised that it would add to the perioperative risk, a similar
observation to that from the randomized trials and the
STS database report.8,10 It is provocative that AFrdiovascular Surgery c Volume 146, Number 4 819
FIGURE 3. Summary of survivorship since surgery (1A-1C) and the last follow-up (2A-2C) by study group by atrial fibrillation (AF) status at the last
follow-up visit. PAF, Paroxysmal atrial fibrillation.
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observed by each analysis.
AF treatment provided apparent benefits. The benefits in
the matched patients appeared to be improved FFAF with-
out AADs at the last follow-up visit for the TrPAF vs Un-
trPAF patients (88% vs 65%, P ¼ .054), although the
FFAF without AADs was not as high as for those with
NoAF (84% vs 93%, P ¼ .001). No difference was seen
in late stroke risk in the overall groups or the matched pairs.
A difference was seen in late survival but not in 30-day820 The Journal of Thoracic and Cardiovascular Surgsurvival. In the original groups and matched patients, the
TrPAF and NoAF groups had very similar survival at all
points out to 5 years. However, the UntrPAF patients had
worse survival than the TrPAF and NoAF groups
(P ¼ .024 unadjusted, P ¼ .099 adjusted). Patients who
were in AF at the last follow-up visit had worse overall sur-
vival in the TrPAF and NoAF groups, but this was not ob-
served in the UntrPAF group.
Although our comparison of the LA and BA lesion sets
was restricted by the small number of patients matched inery c October 2013
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AADs at 1 year (79% vs 90%, P ¼ .10). Soni et al22 re-
viewed the rhythm outcome of 305 patients who had under-
gone AF ablation with a variety of different types of AF. No
difference was found between LA and BA in the FFAF;
however, they found an increased need for pacemaker im-
plantation in the BA group (16.5% vs 7.5%, P ¼ .02). In
our PS-matched comparison of BA and LA, we observed
a rate of pacemaker implantation similar to that of the study
by Soni et al22 (BA 14% vs LA 8%). However, with the
small numbers in our study, the difference did not reach sta-
tistical significance (P ¼ .34). We could not explain the
trend toward better survival for the BA-treated patients.
A randomized clinical trial compared patients with PAF
treated with PVI concomitant to CABG and those who un-
derwent CABG alone.23 They reported an FFAF without
AADs rate of 88.9% at 18 months in the treated group,
very similar to our results (85%) and much lower than
that in their control group (47.1%). Their follow-up proto-
col for both treated and untreated patients included im-
planted devices to track the arrhythmia burden; therefore,
they were much more likely to detect AF in the UntrPAF
group than we were in our study. Gillinov et al24 provided
the only other report on surgical treatment of paroxysmal
AF using different lesions sets and found similar results in
their study among PVI, PVI with LA connecting lesions,
and a Cox maze procedure. Their finding of an FFAF of
84% was similar to that for our TrPAF group.
The present nonrandomized, single-center study had nu-
merous limitations. FFAF was carefully determined by the
postoperative protocol for the TrPAF patients but not for
the others. Therefore, AF might have been present, but un-
detected, in those with NoAF or UntrPAF. However, the
TrPAF patients with AF detected would have been more ag-
gressively treated with medication, cardioversion, or possi-
ble catheter ablation to eliminate the AF. Nevertheless, the
FFAF without AADs was likely not as high as we have re-
ported for the NoAF and UntrPAF patients. Four different
types of lesion sets were applied by 5 different surgeons,
some with more conservative use of ablation (35%) and
others more liberal (85%). Although PS matching was
used to account for the baseline differences in the 3 patient
groups, not all factors could be balanced (the TrPAF pa-
tients had 3-mm larger LA lesions, more preoperative pace-
makers, and more tricuspid valve surgery than the NoAF
surgery group). The most important of these limitations
was that the UntrPAF group might have been ‘‘sicker’’ be-
cause of factors not considered in the PS model that might
have accounted for the reduced survival. However, they
might have been the same at baseline but were untreated,
because they were treated by surgeons with a more conser-
vative approach to AF ablation. Relatively few UntrPAF pa-
tients were available to compare with the TrPAF patients
(n ¼ 80) or NoAF patients (n ¼ 114), but the differencesThe Journal of Thoracic and Caappeared to be small (all P ¼ NS) in the baseline demo-
graphics (except more preoperative pacemakers than in
the NoAF group). Little difference was found in the out-
comes in the LA only vs BA lesions, but the patient numbers
were limited; thus, any inferences should be conservative.CONCLUSIONS
For patients with PAF undergoing cardiac surgery, we
found no apparent penalty to adding an AF ablation proce-
dure. Also, the treated group was associated with decreased
overall perioperative complications and survival similar to
that of the patients with no AF history. A randomized trial
would help address the limitations of our single-center
study. However, we believe selective use of AF ablation
can be performed safely with good midterm FFAF.References
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Dr A. Marc Gillinov (Cleveland, Ohio). Pat, that was a great
study. These sorts of studies require tremendous patience, focus,
and determination, similar to the patience, focus, and determina-
tion you showed when you taught me how to do a maze procedure
almost 20 years ago, and thank you for that.
Paroxysmal AF is an uncommon subject of study in our field,
but it is a really common clinical problem, and what you are doing
is filling the knowledge gap. You have shown that treatment of PAF
is associated with decreased complications, increased freedom
from AF, and increased apparent long-term survival. I have only
2 questions, which I hope will guide me if I am in the operating
room on Monday and I have a patient with PAF.
The first question: which patients with PAF should receive
ablation?822 The Journal of Thoracic and Cardiovascular SurgDrMcCarthy. The decision-making really begins by consider-
ing the operation that the patient needs. If the left atrium is open, it
is easy and quick to add LA ablation, which these days I typically
perform with cryoablation. AF ablation is performed in nearly
100% of that patient group. However, if it is a patient who needs
coronary bypass or aortic valve replacement, especially if it is an
older patient, we tend to just do PVI.
Dr Gillinov. And that gets to my second question: which lesion
set? What is your favorite lesion set and would you alter it if the
patient had, for instance, highly symptomatic PAF? Would the
highly symptomatic patient push you toward a full Cox maze IV
and are there other factors, some that you have mentioned, that
would lead you to perform PVI alone?
Dr McCarthy. Young patients, AF symptomatic patients, and
a stroke history are the 3 clinical factors that really make us
more aggressive in how we treat AF. For that group of patients,
in particular, even if I am doing an aortic valve operation or coro-
nary bypass, I might open the left atrium and do a more complete
lesion set. If I am also doing a tricuspid, it is quick and easy to add
the right atrial lesions, and so you end up with a biatrial lesion set
in that group.
DrVinayBadhwar (Pittsburgh, Pa).Congratulations on awon-
derful presentation and a provocative addition to the published
data. When we are faced with surgically treating patients who
have concomitant PAF, it occasionally becomes an issue of defini-
tion. For example, a patient who reports palpitations or, perhaps,
has a remote electrocardiogram for the preoperative workup show-
ing they are actually not in AF.
For your study, did you have some rigor in the documentation or
definition of PAF?
DrMcCarthy.All the patients had to have documented electro-
cardiographic evidence that they had had AF in the past. We did
not accept clinical symptoms that suggested AF without electro-
cardiographic documentation. If we saw preoperative patients
with that history, we always sent them for a 48-hour Holter monitor
test before surgery just to be certain. Also, we have 2 AF nurses
whose full-time job is to help with the assessment of those patients
and perform the follow-up. Thus, they are pretty careful about get-
ting good data about preoperative AF, in accordance with the HRS
document.
Dr Takashi Nitta (Tokyo, Japan). I have 2 questions. First, how
many of the patients in the untreated AF group developed perma-
nent AF during your follow-up period?
Dr McCarthy. That is a good question. We were just recording
how many went into AF. We did not actually, in the present study,
determine whether they were still in PAF. We were just reporting
according to the HRS guidelines. However, we should be able to
tease that information out to see howmany progressed to persistent
or longstanding persistent AF.
Dr Nitta. Second, did you study the recurrence or progression
of mitral valve regurgitation in the untreated AF group, because
1 of the reasons for the poorer outcomes in the untreated group
might have been the progression or recurrence of mitral valve
regurgitation.
Dr McCarthy. I think you were asking, if we were treating for
coronary bypass or aortic valve disease, and we were not treating
for the mitral valve, was there some progression of mitral valve
disease, and, no, we did not include that in this study.ery c October 2013
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as always. You did not really present the stroke data, although
you did state in the abstract that it was the same among all the
groups. I assume that was because it was pretty low. Did it
surprise you that in the untreated PAF group the later stroke
rate was not high?
DrMcCarthy.No. I think all those patients would have contin-
ued to takewarfarin. However, you are right, in the study, no differ-
encewas found in the stroke rate. The data continued out to 5 years.
It also was not a huge population of patients being followed up.
Dr Bolling. In the treated PAF group, I assume you took all the
appendages or dealt with the appendages. In the untreated group,
do you do anything with the appendage?
Dr McCarthy. In the untreated AF group, if we were there for
mitral disease, that was a very small number, we likely treated the
appendage. However, in the group with aortic valve or coronary
bypass, not necessarily, especially in reoperations.
Dr Bolling. And then the last question. How did you handle
warfarin in all the patients?
DrMcCarthy.We have a pretty strict protocol in how we man-
age warfarin and AF. At 3 months, the AF nurses obtain a Holter
monitor recording for every patient, and if they are free of AF
and free of AF symptoms, we stop their AADs, usually amiodar-
one. Then, we recheck them at 6 months after that has washed
out with another Holter monitor or pacemaker interrogation, and
only then will we consider stopping warfarin. We also use the
CHA2DS2-VASc to help guide whether to stop it.
Dr Niv Ad (Falls Church, Va). Excellent presentation. One
quick question because I might have overheard, but did you men-
tion that if you have an aortic valve or CABG you are reluctant to
open the left atrium, and if so, why, because we have shown, and
others have shown, that even if you perform a full Cox mazeThe Journal of Thoracic and Caprocedure on these patients you do not increase the risk of surgery
like any other procedure.
Dr McCarthy. I said we do it less often, especially in the PAF
patient population. It depends on the age of the patient and their
general condition. So, for instance, if it is an 89yearold patient
who has had 3 episodes of PAF before surgery, I will do a mini-
mally invasive aortic valve replacement, and I would not perform
a sternotomy and then open the left atrium to treat that. That has
just been our approach.
Dr Ad. The 1 potential hazard, especially with patients with
aortic stenosis, is that you open the gate for LA atypical flutter.
So, if the patient is too sick, perhaps just remove the appendage
and leave the rest as is and not set up for worse arrhythmia.
Dr McCarthy. So you are saying if you do just PVI, you might
set them up for atrial flutter?
Dr Ad. Yes.
Dr McCarthy. That is a group of patients that we would not
necessarily treat at all in that older patient population, but we
did not observe that in the PVI-treated population.
Dr Ralph J. Damiano (St. Louis, Mo). If I understood it cor-
rectly, you reported your results as FFAF at the last follow-up visit.
Dr McCarthy. Without AADs, yes.
Dr Damiano. The present guidelines have suggested that suc-
cess should be defined as FFAF and AADs at 12 months. Thus,
if you considered the data that way, which is a little more rigorous,
because the last follow-up visit is very hard to know, it might be 1
month, 3 months, we do not know, but does that change any of your
conclusions?
Dr McCarthy. The last follow-up visit averaged 2.8 years in
this group, and in the report, actually we do include all the various
combinations. However, in a 10-minute talk I could not show all
the various combinations.rdiovascular Surgery c Volume 146, Number 4 823
